Journey Medical Co. (NASDAQ:DERM) CEO Sells $122,006.52 in Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 23,508 shares of Journey Medical stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $5.19, for a total transaction of $122,006.52. Following the transaction, the chief executive officer now directly owns 2,139,922 shares of the company’s stock, valued at $11,106,195.18. This represents a 1.09 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Claude Maraoui also recently made the following trade(s):

• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total value of $93,094.11.

Journey Medical Stock Down 3.3 %

Shares of NASDAQ:DERM opened at $5.06 on Friday. The business’s 50-day moving average is $4.56 and its 200-day moving average is $5.07. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89. The company has a market capitalization of $105.70 million, a price-to-earnings ratio of -5.38 and a beta of 0.96. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03.

Hedge Funds Weigh In On Journey Medical

Several institutional investors have recently added to or reduced their stakes in DERM. Tang Capital Management LLC acquired a new stake in shares of Journey Medical during the 4th quarter worth approximately $6,747,000. PVG Asset Management Corp boosted its stake in Journey Medical by 5.7% during the third quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock worth $947,000 after acquiring an additional 9,005 shares in the last quarter. Geode Capital Management LLC grew its holdings in Journey Medical by 13.5% in the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after purchasing an additional 12,882 shares during the period. Citadel Advisors LLC bought a new stake in Journey Medical in the fourth quarter valued at $174,000. Finally, Kovitz Investment Group Partners LLC raised its holdings in shares of Journey Medical by 112.9% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock valued at $97,000 after purchasing an additional 13,105 shares during the period. 7.25% of the stock is owned by institutional investors and hedge funds.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.